Deze Li

Dr. Deze Li

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
HCHao Chen
Hao Chen
Background: A dual-axis organization of non-alveolar macrophages—scar-associated SPP1+ and tissue-resident-like FOLR2+ populations—was recently delineated in idiopathic pulmonary fibrosis (IPF), but their functions and niches remain unresolved. Methods: We integrated full-transcriptome re-clustering of the GSE135893 myeloid compartment, independent replication (GSE136831), and GeoMx spatial profiling of bronchiolitis obliterans and fibrosing ILD lesions (GSE316672, GSE255174). Results: Two IPF-emergent entities were confirmed and first systematically quantified: SPP1+/TREM2+ scar-associated macrophages (97% IPF-derived; 4.0% to 30.7% of macrophages) and the FOLR2+/CD163+/SLC40A1+ iron-handling population (95% IPF; 11.9% to 19.0%). Both axes replicated in the Adams cohort (donor-level p = 1.2 × 10⁻⁵ and 8.2 × 10⁻¹¹). Spatial profiling revealed a core-and-ring architecture in BO lesions (SPP1+/TREM2+ luminal core; MCL1-high scavenger ring). Monocyte flux correlated with fibroblast apoptotic priming (rho = +0.54; nominal p = 0.045). No canonical M1/M2a enrichment was detected; the FOLR2+ efferocytosis arm was MERTK/GAS6-dominant across cohorts. Conclusion: The fibrotic lung’s dual-axis macrophage architecture is functionally attributed and spatially resolved, with implications for combination targeting.

29 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
HCHao Chen
Hao Chen
Diagnosing Mycoplasma pneumoniae (MP) has followed three technological paths — seeing the organism, reading the host's antibodies, reading the pathogen's genome — and the winners were rarely the best assays. Culture was analytically supreme and never adopted; serology ruled the clinic for fifty years despite documented misclassification; PCR outperformed both by 1990 yet took a decade and a half to reach routine use. We reconstructed 120 years of MP diagnostics as a diffusion dataset, scoring each technology on Rogers' five adoption attributes against its contemporaneous competitor, and tested the scores against regulatory archives (FDA, CE-IVD, China NMPA; search concluded 30 September 2026). Every documented displacement is consistent with four empirical laws: relative advantage in time-to-result outweighed analytic accuracy; workflow compatibility decided more contests than sensitivity; displacement occurred when a successor's turnaround crossed the clinical decision window; and adoption lagged roughly a decade behind technological maturity (mean 8.5 years across the eight measurable transitions) — a severity-gated lag that relaxed measurably after the 2023 resurgence. Applying the validated rubric prospectively, we predict that CRISPR-based point-of-care testing will obtain first regulatory approvals (NMPA before FDA) by end-2027 and achieve decisive adoption in pediatric emergency settings by end-2028, conditional on extraction-free, sample-to-answer workflow, while metagenomic sequencing consolidates in severe and atypical niches without crossing into first-line use before 2030. The predictions are falsifiable and dated — the archive is offered as an evaluation instrument, not an opinion.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
HCHao Chen
Hao Chen
Mycoplasma pneumoniae (MP) infects tens of millions of children in an epidemic year, yet registers as a rounding error in the mortality metrics by which global health allocates resources. We audited this invisibility by triangulating three evidence streams: six national and multinational surveillance systems; a M. pneumoniae–specific secondary analysis of Global Burden of Disease (GBD) 2023 data; and GBD-derived counterfactual projections of the 2023 resurgence extrapolated from pre-pandemic epidemic cycles. Under non-pharmaceutical interventions (NPIs), MP disappeared more completely and for longer than influenza or RSV; it returned along a policy-timed interval gradient — 6–7 months after NPI relaxation in China, 21–22 months in Japan — exceeding the no-COVID counterfactual projection by 19.2%, breaching its upper prediction interval. Modeled MP mortality in children aged 0–19 years (26,382 deaths, 95% uncertainty interval (UI) 18,984–36,012; ninth of 26 modeled lower respiratory infection (LRI) etiologies) concentrated where measurement is absent: 81.6% of estimated deaths in sub-Saharan Africa and South Asia, while infections peak at school ages where death is rarest — an infection–mortality dissociation that no single instrument of global health accounting can see. Chronic sequelae compound the omission: bronchiolitis obliterans developed in 7.3% of the largest post-pneumonia follow-up cohort, converting a survivable infection into decades of disability invisible to mortality-weighted metrics. The 2023–2024 resurgence was not an anomaly but an audit finding — a structural failure of measurement, not of biology. We propose five corrections with named institutional owners: MP-specific sentinel surveillance, sequelae-weighted burden metrics, resistance-stewardship infrastructure, diagnostic adoption standards, and vaccine prioritization.

28 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HCHao Chen
Hao Chen
DLDeze Li
Deze Li
CSChen Shen
Chen Shen
Introduction: Which of the two leading infectious killers of children—lower respiratory infections (LRIs) or diarrheal diseases—ends first should order child-survival investments, yet whether their transitions are symmetric is unknown. We compared the systems on a single counterfactual scale—a cross-system death-ratio series with formal uncertainty—at ages 0–19 years in the Global Burden of Disease Study (GBD) 2023. Methods: We extracted deaths and incident episodes, 1990–2023, from the GBD 2023 Results Tool, aggregating the under-5 band plus ages 5–9, 10–14 and 15–19. We computed cross-system death-ratio series, estimated annual percentage changes (EAPCs), pandemic-window changes with Monte Carlo uncertainty, an episode-fatality ratio proxy (EFR; deaths per 1,000 episodes, for 204 countries in 2023), and cross-system Escherichia coli trend correlations. Results: In 1990 the systems were indistinguishable (2.04 million LRI versus 2.00 million diarrhea deaths; ratio 0.98, 95% uncertainty interval 0.74–1.31). By 2023, LRI deaths (711,713) exceeded diarrhea deaths (379,958) 1.87-fold (ratio 0.53, 0.36–0.79; parity first excluded in 2013 and in every year thereafter except the 2020–2021 pandemic window). Improvement was age-synchronous for diarrhea but age-asymmetric for LRI (5–19-year EAPC −4.48% versus −1.74% per year). The pandemic window suppressed then released LRI deaths (year-on-year −18.4%, −9.0%, +12.8%, +8.1%; rebound in all five Socio-demographic Index quintiles) while diarrhea declined monotonically. Fatality gradients widened twice over: the 2023 LRI EFR was 49 times the diarrhea EFR; the low-to-high-SDI gradient steepened from 2.58 to 7.29 (LRI) and 6.40 to 22.50 (diarrhea); and country-level diarrhea EFRs tracked GDP per capita (ρ=−0.76) and LRI EFRs (ρ=0.85). E. coli mortality, coupled across systems until 2010 (ρ=1.000), decoupled thereafter (ρ=0.371): enteric deaths halved, respiratory deaths plateaued. Conclusion: The two systems share a starting point but no longer a trajectory. Pediatric infection frameworks should treat fatality, not incidence, as the binding constraint for LRI and extend case management and surveillance to the school-age children the transition has left behind.

31 July 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
CSChen Shen
Chen Shen
DLDeze Li
Deze Li
WXwang xiaotong
wang xiaotong
YSYang Sun
Yang Sun
HZHuiwen Zheng
Huiwen Zheng
SZShunying Zhao
Shunying Zhao
Background: Severe Mycoplasma pneumoniae pneumonia (SMPP) presents with heterogeneous clinical complications and imaging manifestations, including pleural effusion (PE), bronchiolitis obliterans (BO), and distinct imaging/bronchoscopic phenotypes. The precise systemic immune subpopulation dynamics underlying these distinct phenotypes remain poorly defined. Methods: We conducted flow cytometric profiling of peripheral blood mononuclear cells (PBMCs) from pediatric patients to compare mild MPP (MMPP-N) and severe MPP subtypes. SMPP patients were stratified into subgroups including those with BO (SMPP&BO, n = 3), PE (SMPP&PE), and three imaging/bronchoscopic phenotypes: Group A (SMPP-GA, mucous plugs), Group B (SMPP-GB, mucosal necrosis), and Group C (SMPP-GC, diffuse bronchiolitis). Composite immune indices and multi-marker discriminant analysis were constructed for secondary analysis. Results: Comprehensive high-dimensional profiling suggested that a fundamental innate-adaptive immune rebalancing may represent a key pathophysiological axis in severe disease. Patients with PE exhibited massive CD16− monocyte expansion (Delta = 40.0%) coupled with CD8+ Teff collapse (Delta = −9.2%). Preliminary data also suggest BO may be marked by CD56−CD11C+ monocyte depletion (Delta = −23.1%, n = 3), warranting further validation. Imaging subgroup profiling revealed that SMPP-GC featured major B-cell maturation alterations (HLADR+CD45RAhigh expansion and CD38+CD25low depletion). Composite indices including the Adaptive Exhaustion Score suggested discriminatory power (AUC = 0.90 for PE vs. uncomplicated SMPP). The Innate-Adaptive Ratio increased progressively with severity (Spearman rho = +0.40, p = 0.0002). Conclusions: SMPP is not immunologically uniform. Innate-adaptive rebalancing underlies complication-specific phenotypes: inflammatory monocyte mobilization with adaptive exhaustion is strongly associated with PE, whereas B-cell maturation alterations characterize diffuse bronchiolitis. These findings identify potential biomarker candidates for patient stratification, though small-cohort observations require extensive validation in larger prospective studies.

1 June 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
SSSong Sun
Song Sun
BMBoyang Meng
Boyang Meng
JSJinghao Sang
Jinghao Sang
WLWei Liu
Wei Liu
YZYingkai Zhang
Yingkai Zhang
LCLimin Chai
Limin Chai
This study investigates the functional role and mechanisms of Guilu Erxian Glue (GEG) in regulating immune homeostasis to treat bone marrow (BM) failure in aplastic anemia (AA). Differentially expressed miRNAs of AA patients were identified through bioinformatics analysis of the Gene Expression Omnibus (GEO) database, followed by enrichment analysis of the identified miRNAs and their predicted target genes. The chemical profile of GEG was characterized by UPLC-MS/MS. An AA mouse model was established via 60Co γ-ray irradiation combined with the infusion of an allogeneic lymphocyte suspension for immune induction. GEG + Immunosuppressive therapy (IST) was administered as the therapeutic intervention, with IST + Eltrombopag (EPAG) serving as the positive control. Bone marrow hematopoietic function was evaluated via hematological parameters, BM histopathology, and flow cytometry. CyTOF-2 mass cytometry was utilized to analyze the differentiation profile of CD4+ T-cell subsets, and flow cytometry was further used to detect the proliferation and differentiation of naïve T cells, Tregs, and follicular helper T cells (Tfh). The expression of genes and proteins involved in the miRNA-17/IKZF4, miRNA-10a/BCL6, and Fas pathways was quantified by RT-qPCR and Western blot, with serum cytokines measured by enzyme-linked immunosorbent assay (ELISA). Bioinformatic analysis of the GSE82095 dataset identified significantly dysregulated miRNAs in T cells from AA patients, specifically miRNA-17-5p and miRNA-10a-5p. Preliminary enrichment analysis indicated that these miRNAs are primarily involved in hypoxic stress, T-cell differentiation, and apoptosis. Subsequently, the downstream target genes of these miRNAs were predicted, and further functional enrichment analysis corroborated that these target genes are critically associated with T-cell differentiation. HPLC-MS/MS identified 22 compounds from the aqueous extract of GEG. In vivo, GEG treatment significantly improved BM histopathology and restored peripheral blood counts. It also reduced the percentages of Tfh, Th1, Th17, and effector memory T cells (Tem) (P < 0.01), while increasing the percentages of Tregs and central memory T cells (Tcm) (P < 0.01). Molecular analysis revealed that GEG upregulated miRNA-10a and downregulated miRNA-17 in Tregs (P < 0.01), leading to increased expression of the Foxp3 cofactor IKZF4 and decreased BCL6 expression (P < 0.01). GEG elevated Foxp3 protein levels and inhibited cleaved caspase-3 expression in Tregs, and reduced the levels of pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-6) (P < 0.01),while enhancing the secretion of anti-inflammatory cytokines (IL-10 and IL-35) (P < 0.01). Our findings suggest that GEG contributes to Treg lineage stability and survival through the potential modulation of the miRNA-17/IKZF4, miRNA-10a/BCL6, and Fas/FasL signaling axes. These synergistic effects appear to support the remodeling of T-cell homeostasis and restoration of cytokine balance, offering a promising, miRNA-targeted strategy for enhancing AA therapy that warrants further clinical investigation.